SG11201505111TA - Nanoparticle compositions of albumin and paclitaxel - Google Patents

Nanoparticle compositions of albumin and paclitaxel

Info

Publication number
SG11201505111TA
SG11201505111TA SG11201505111TA SG11201505111TA SG11201505111TA SG 11201505111T A SG11201505111T A SG 11201505111TA SG 11201505111T A SG11201505111T A SG 11201505111TA SG 11201505111T A SG11201505111T A SG 11201505111TA SG 11201505111T A SG11201505111T A SG 11201505111TA
Authority
SG
Singapore
Prior art keywords
paclitaxel
albumin
nanoparticle compositions
nanoparticle
compositions
Prior art date
Application number
SG11201505111TA
Other languages
English (en)
Inventor
Neil P Desai
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of SG11201505111TA publication Critical patent/SG11201505111TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5169Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11201505111TA 2012-12-28 2013-12-19 Nanoparticle compositions of albumin and paclitaxel SG11201505111TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261747123P 2012-12-28 2012-12-28
US13/794,705 US20140186447A1 (en) 2012-12-28 2013-03-11 Nanoparticle compositions of albumin and paclitaxel
PCT/US2013/076630 WO2014105644A1 (en) 2012-12-28 2013-12-19 Nanoparticle compositions of albumin and paclitaxel

Publications (1)

Publication Number Publication Date
SG11201505111TA true SG11201505111TA (en) 2015-07-30

Family

ID=51017455

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201505111TA SG11201505111TA (en) 2012-12-28 2013-12-19 Nanoparticle compositions of albumin and paclitaxel

Country Status (19)

Country Link
US (2) US20140186447A1 (ja)
EP (1) EP2938340A4 (ja)
JP (2) JP2016504362A (ja)
KR (1) KR20150100903A (ja)
CN (1) CN105007912A (ja)
AU (1) AU2013370955B2 (ja)
BR (1) BR112015015319A2 (ja)
CA (1) CA2896288A1 (ja)
CR (1) CR20150386A (ja)
HK (1) HK1216611A1 (ja)
IL (1) IL239593A0 (ja)
MX (1) MX2015008361A (ja)
NI (1) NI201500090A (ja)
NZ (1) NZ630912A (ja)
PH (1) PH12015501486B1 (ja)
RU (1) RU2663687C2 (ja)
SG (1) SG11201505111TA (ja)
WO (1) WO2014105644A1 (ja)
ZA (1) ZA201504762B (ja)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2685436T3 (es) 2002-12-09 2018-10-09 Abraxis Bioscience, Llc Composiciones y procedimientos para administración de agentes farmacológicos
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
PL3311805T3 (pl) 2005-08-31 2020-07-27 Abraxis Bioscience, Llc Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe
ES2700074T3 (es) 2006-12-14 2019-02-13 Abraxis Bioscience Llc Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano
US8927019B2 (en) * 2007-06-01 2015-01-06 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
JP5781500B2 (ja) 2009-04-15 2015-09-24 アブラクシス バイオサイエンス, エルエルシー プリオンを含まないナノ粒子組成物および方法
JP5847156B2 (ja) 2010-03-26 2016-01-20 アブラクシス バイオサイエンス, エルエルシー 肝細胞がんの処置方法
SG10201906075VA (en) 2010-03-29 2019-08-27 Abraxis Bioscience Llc Methods of treating cancer
CN105147613A (zh) 2010-03-29 2015-12-16 阿布拉科斯生物科学有限公司 增强药物递送和治疗剂有效性的方法
WO2011153010A1 (en) 2010-06-04 2011-12-08 Abraxis Biosciences, Llc Methods of treatment of pancreatic cancer
WO2012149451A1 (en) 2011-04-28 2012-11-01 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
EP2707030B1 (en) 2011-05-09 2020-02-19 Mayo Foundation For Medical Education And Research Cancer treatments
KR102203555B1 (ko) 2011-12-14 2021-01-14 아브락시스 바이오사이언스, 엘엘씨 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도
WO2014055415A1 (en) 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
US10744110B2 (en) 2013-03-12 2020-08-18 Abraxis Bioscience, Llc Methods of treating lung cancer
WO2014151853A1 (en) 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
KR102245421B1 (ko) 2013-05-30 2021-04-29 큐라디즘 약학적 조성물, 이의 제조방법 및 이의 용도
US10213513B2 (en) 2014-06-16 2019-02-26 Mayo Foundation For Medical Education And Research Treating myelomas
CN104224750A (zh) * 2014-09-17 2014-12-24 四川大学 一种注射用卡巴他赛白蛋白纳米粒制剂及其制备方法
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
ES2774365T3 (es) * 2014-11-25 2020-07-20 Curadigm Sas Composición farmacéutica, preparación y usos de la misma
SG11201704219UA (en) 2014-11-25 2017-06-29 Nanobiotix Pharmaceutical composition, preparation and uses thereof
AR102780A1 (es) 2014-11-25 2017-03-22 Nanobiotix Composiciones farmacéuticas, su preparación y sus usos
FI3229776T3 (fi) 2014-11-25 2023-08-15 Curadigm Sas Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt
US10527604B1 (en) * 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
EA201792560A1 (ru) 2015-05-28 2018-06-29 Нанобиотикс Наночастицы для применения в качестве терапевтической вакцины
KR102606071B1 (ko) 2015-06-29 2023-11-27 아브락시스 바이오사이언스, 엘엘씨 상피양 세포 종양을 치료하는 방법
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
CA3014531A1 (en) * 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
CA3018341A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
MX2019002474A (es) 2016-09-01 2019-09-18 Mayo Found Medical Education & Res Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres.
EP3506950A1 (en) 2016-09-01 2019-07-10 Mayo Foundation for Medical Education and Research Methods and compositions for targeting t-cell cancers
WO2018048815A1 (en) 2016-09-06 2018-03-15 Nantibodyfc, Llc Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
KR20230010817A (ko) 2016-09-06 2023-01-19 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 파클리탁셀-알부민-결합제 조성물 및 그의 사용 및 제조 방법
CN109843924A (zh) 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
CN106420665B (zh) * 2016-10-28 2019-04-16 浙江省林业科学研究院 一种包裹紫杉烷类药物的白蛋白纳米颗粒载体的制备方法
WO2019070850A1 (en) * 2017-10-03 2019-04-11 Crititech, Inc. LOCAL ADMINISTRATION OF ANINEOPLASTIC PARTICLES IN COMBINATION WITH SYSTEMIC DELIVERY OF IMMUNOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
EP3768268A4 (en) 2018-03-20 2022-02-23 Abraxis BioScience, LLC METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE
WO2021050799A1 (en) * 2019-09-13 2021-03-18 Purdue Research Foundation Compositions and methods for cancer treatment by enhancing antitumor immunity using tannic acid-based nanocapsules
BR112022007710A2 (pt) * 2019-10-28 2022-07-12 Abraxis Bioscience Llc Composições farmacêuticas de albumina e rapamicina
BR112022009018A2 (pt) * 2019-11-11 2022-10-11 Abraxis Bioscience Llc Biomarcadores para composições de nanopartícula
US20230074885A1 (en) * 2020-02-05 2023-03-09 The Johns Hopkins University Bortezomib-loaded nanoparticles
EP4375659A1 (en) * 2022-11-28 2024-05-29 Takeda Vaccines, Inc. A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
EP1100494A1 (en) * 1998-07-30 2001-05-23 Novopharm Biotech, Inc. Pharmaceutically composition comprising an aqueous solution of paclitaxel and albumin
JP4798832B2 (ja) * 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 ヒト血清アルブミン多量体の除去方法
DK2470173T3 (en) * 2009-08-25 2016-06-06 Abraxis Bioscience Llc Combination therapy of nanoparticle composition of the taxane and the hedgehog inhibitors
JP5847156B2 (ja) * 2010-03-26 2016-01-20 アブラクシス バイオサイエンス, エルエルシー 肝細胞がんの処置方法
WO2012092712A1 (zh) * 2011-01-07 2012-07-12 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的纳米颗粒冷冻干燥粉末制剂
CN102078306A (zh) * 2011-01-11 2011-06-01 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的紫杉醇纳米颗粒冷冻干燥制剂

Also Published As

Publication number Publication date
CR20150386A (es) 2015-10-07
PH12015501486A1 (en) 2015-09-21
HK1216611A1 (zh) 2016-11-25
JP2018087241A (ja) 2018-06-07
KR20150100903A (ko) 2015-09-02
RU2015131141A (ru) 2017-02-03
RU2663687C2 (ru) 2018-08-08
NZ630912A (en) 2017-05-26
EP2938340A1 (en) 2015-11-04
IL239593A0 (en) 2015-08-31
NI201500090A (es) 2015-12-22
CA2896288A1 (en) 2014-07-03
US20140186447A1 (en) 2014-07-03
WO2014105644A1 (en) 2014-07-03
JP2016504362A (ja) 2016-02-12
US20190192477A1 (en) 2019-06-27
EP2938340A4 (en) 2016-08-03
BR112015015319A2 (pt) 2017-07-11
PH12015501486B1 (en) 2015-09-21
ZA201504762B (en) 2016-10-26
AU2013370955A1 (en) 2015-07-16
MX2015008361A (es) 2016-03-11
CN105007912A (zh) 2015-10-28
AU2013370955B2 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
HK1216611A1 (zh) 白蛋白和紫杉醇的納米顆粒組合物
IL272313A (en) Intravascular delivery of nanoparticle preparations and their uses
IL252566A0 (en) Pharmacy preparations and methods
EP2852381A4 (en) LIPID NANOPARTICLE COMPOSITIONS AND METHOD FOR THE PREPARATION AND METHOD FOR USE THEREOF
IL237156B (en) Microcapsule preparation and methods
IL236024A (en) The history of benzimidazole-proline and its pharmaceutical preparations
EP2814496A4 (en) NANOPARTICLES FOR MITOCHONDRIAL TRANSPORT OF ACTIVE SUBSTANCES
HK1214348A1 (zh) 用於檢測維生素 的組合物和方法
EP2697162A4 (en) DESIGNS AND APPLICATIONS FOR MULTIFUNCTIONAL NANOPARTICLES
HK1211862A1 (en) Nanoparticle formulation
ZA201501124B (en) Trans-clomiphene formulations and uses thereof
HK1216250A1 (zh) '- '-羥基-二氫麥角胺化合物及組合物
CY2200004T2 (el) Σκευασματα δαπτομυκινης και χρησεις αυτων
EP2887954A4 (en) NEUROTHERAPEUTIC NANOPARTICLE COMPOSITIONS AND DEVICES THEREWITH
EP2874641A4 (en) COMPOSITIONS INCREASING THE GLUTATHION RATE AND USES THEREOF
PT2790739T (pt) Nanopartículas e utilizações das mesmas
IL233961A0 (en) The composition of a phytogenic supplement and methods of its use
EP2841083A4 (en) BIS POLYMER LIPID PEPTIDE CONJUGATES AND NANOPARTICLES THEREOF
IL235154A0 (en) Preparations containing substances to reduce uric acid and anti-inflammatory substances and their uses
EP2834635A4 (en) COMPOSITIONS WITH A HEPARINE ACCUMULATIVE AND METHOD THEREFOR
GB201208315D0 (en) Pharmaceutical methods and compositions
EP2861586A4 (en) FORMS OF VILAZODONE AND METHODS OF PREPARATION THEREOF
EP2838365A4 (en) ANTIMICROBIAL COMPOSITIONS AND USES THEREOF
HUE032878T2 (hu) Bõrvédõ és bõrkiegyensúlyozó készítmény
EP2841164A4 (en) COMPOSITIONS AND USE PROCEDURES FOR THE SKIN